Mohamed from Bahrain

Registered at the short selling broker Capital, 2 minutes ago.

» Try Capital you too
67.7% of retail investor accounts lose money when trading CFDs with Capital.
Don't show again

Takeda Pharmaceutical Co., Ltd (TAK) shares information

Takeda Pharmaceutical Co – ADR


24h Change

-0.24 %

TAK

Live rate: Market closed

Stock data per Tuesday 28 Mar, 2023

TAK
NEW YORK STOCK EXCHANGE INC.
16.48
16.4
16.44
-0.04 (-0.24%)
US Market is closed

Live Stock price in graph for Takeda Pharmaceutical Co – ADR (TAK)

  • Latest Volume

    1,173,517 (-47.15 %)

  • Volume prev. day

    2,220,673

  • Avg. daily volume

    2,556,875

  • Market cap

    52,025,880,150

  • P/E ratio

    22.16

  • Today high

    16.49 USD

  • Today low

    16.385 USD

  • 52 week high

    16.58 USD

  • 52 week low

    12.28 USD

  • YTD Change

    + 5.40 %

Quick links

 

Latest news about Takeda Pharmaceutical Co – ADR

Below you can find the most recent news posts about Takeda Pharmaceutical Co – ADR, primarily from US and UK based news sources.

Global Adrenal Crisis Management Market to Surpass US$ 6.31 Million by 2033; Intravenous Injections to Comprise 53% of all Drug Delivery Modes | Future Market Insights, Inc.

Wednesday, 22 March 2023, 13:00:00
NEWARK, DE / ACCESSWIRE / March 22, 2023 / During the forecast period 2023 to 2033, the Adrenal Crisis Management Market is expected to grow at a value of 6.7% CAGR , according to Future Market Insights. By the year 2033, the global market for Adrenal crisis management is expected to rise up to a market valuation of US$ 6.31 million . Growth of the market can be attributed to factors such as the increasing prevalence of adrenal insufficiency, technological advancements, and rising awareness about the condition. One of the key drivers of the adrenal crisis management market is the increasing prevalence of adrenal insufficiency. The rising prevalence of adrenal insufficiency is due to a number of factors, including autoimmune disorders, infections, and the use of certain medications. As the population ages, the incidence of adrenal insufficiency is likely to increase, driving demand for adrenal crisis management products and services. For More Insights on this Market, Get A Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16826 Technological advancements have also played a key role in the growth of the adrenal crisis management market.
— Accesswire


Takeda: Pipeline Expanding But Growth Worries Persist (NYSE:TAK)

Thursday, 16 March 2023, 12:35:38
Takeda”s late-stage pipeline is impressive with many candidates boasting very strong fundamentals. See why we are neutral on TAK stock.
— Seeking Alpha


Cell Therapy Market Size & Share to Surpass USD 16.1 Billion by 2028 | Vantage Market Research

Monday, 13 March 2023, 12:44:15
WASHINGTON, March 13, 2023 (GLOBE NEWSWIRE) — Global Cell Therapy Market was valued at USD 10.1 Billion in 2021 and is expected to reach USD 16.1 Billion by 2028, growing at a CAGR of 12.3% from 2022 to 2028. according to a report published by Vantage Market Research. North America currently dominates the market due to the presence of established pharmaceutical and biotechnology companies, as well as favorable government policies. Get Access to the In-depth Free Sample Report @ https://www.vantagemarketresearch.com/cell-therapy-market-1236/request-sample Cell Therapy Market Overview Cell therapy is a type of regenerative medicine that uses living cells to treat or cure diseases. The cell therapy market has been growing rapidly in recent years due to the increasing prevalence of chronic diseases, such as cancer and autoimmune disorders, and the growing need for personalized medicine. The market is segmented based on the type of therapy, cell source, application, end-user, and region. The major types of cell therapy include autologous, allogeneic, and others.
— Benzinga


Blood Cancer Drugs Global Market Report 2023

Thursday, 23 February 2023, 16:38:00
Major players in the blood cancer drugs market are Amgen Inc., AstraZeneca PLC, Bayer AG, Celgene Corporation, Eli Lilly, Johnson & Johnson, Novartis, Pfizer Inc, AbbVie Inc. and Takeda Pharmaceutical Company Ltd. Major players in the blood cancer drugs market are Amgen Inc., AstraZeneca PLC, Bayer AG, Celgene Corporation, Eli Lilly, Johnson & Johnson, Novartis, Pfizer Inc, AbbVie Inc. and Takeda Pharmaceutical Company Ltd.
— GlobeNewswire


Schrödinger gets $111.3M linked to Takeda”s acquisition of Nimbus” psoriasis drug

Tuesday, 14 February 2023, 13:31:02
Schrödinger (SDGR) said it received $111.3M cash distribution from Nimbus Therapeutics, in connection with Takeda Pharmaceutical”s acquisition of Nimbus Lakshmi.In December 2022,…
— Seeking Alpha


Trading broker recommendation

We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €250 by bank
Description: Capital.com offer a large number of stocks for trading. Register an account today and check if they have TAK available or trade one of the many other CFD stocks they have.
Risk warning: 67.7% of retail investor accounts lose money when trading CFDs with Capital.